Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ranibizumab vs Verteporfin PDT in CNV secondary to Pathologic Myopia
NCT01217944Phase 3Completed
- Sponsor
- Novartis
- Start
- Oct 2010
- Primary completion
- Aug 2012
- Modality
- Antibody Fragments, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 20
01
Overview
A Phase 3 trial of ranibizumab in choroidal neovascularization (CNV), sponsored by Novartis. Started Oct 2010; status: completed.
02
Drugs
ranibizumab
03
Conditions
choroidal neovascularization (CNV)
Beyond the preview
Go deeper on NCT01217944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01217944.